

# Jeanny B Aragon-Ching

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5608796/jeanny-b-aragon-ching-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

2,809  
citations

26  
h-index

51  
g-index

153  
ext. papers

3,413  
ext. citations

6.2  
avg. IF

5.42  
L-index

#	Paper	IF	Citations
137	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1218-1230	59.2	294
136	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2014</b> , 64, 225-49	220.7	258
135	Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4200-5	12.9	177
134	A phase II clinical trial of sorafenib in androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 209-14	12.9	151
133	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2266-2277	40	121
132	Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1411-6	12.9	118
131	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , <b>2007</b> , 12, 4957-71	2.8	118
130	ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4543-9	12.9	117
129	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2009</b> , 103, 1636-40	5.6	102
128	Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. <i>Cancer Investigation</i> , <b>2009</b> , 27, 221-6	2.1	102
127	CNS metastasis: an old problem in a new guise. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1644-7	12.9	79
126	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1341-1367	2.2	75
125	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1500-9	2.2	65
124	Thalidomide analogues as anticancer drugs. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2007</b> , 2, 167-74	4.6	55
123	Phase I study of oral lenalidomide in patients with refractory metastatic cancer. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 650-60	2.9	45
122	VEGF inhibitors and prostate cancer therapy. <i>Current Molecular Pharmacology</i> , <b>2009</b> , 2, 161-8	3.7	44
121	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, LBA1-LBA1	2.2	44

120	Role of chemotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2018</b> , 20, 221-229	2.8	43
119	The changing landscape in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2013</b> , 5, 25-40	5.4	38
118	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 105-120	21.7	35
117	A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. <i>Journal of Urology</i> , <b>2009</b> , 181, 1104-13; discussion 1113	2.5	33
116	Vitamin D in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2018</b> , 20, 244-252	2.8	32
115	Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. <i>Prostate Cancer</i> , <b>2013</b> , 2013, 210686	1.9	30
114	Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. <i>Journal of Urology</i> , <b>2008</b> , 180, 1432-7; discussion 1437	2.5	30
113	The role of angiogenesis inhibitors in prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2008</b> , 14, 20-5	2.2	27
112	The evolution of prostate cancer therapy: targeting the androgen receptor. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 295	5.3	26
111	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10, 57-66	1.8	25
110	Angiogenesis inhibition in prostate cancer: current uses and future promises. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 361836	4.5	24
109	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10, 11-9	1.8	22
108	Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 307-318	7.1	21
107	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 229-37	3.3	20
106	Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	18
105	Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. <i>Acta Oncologica</i> , <b>2008</b> , 47, 1600-1	3.2	18
104	The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2019</b> , 13, 1179554919833927	1.8	17
103	Anti-angiogenesis approach to genitourinary cancer treatment. <i>Update on Cancer Therapeutics</i> , <b>2009</b> , 3, 182-188		16

102	Metastatic castration-resistant prostate cancer: critical review of enzalutamide. <i>Clinical Medicine Insights: Oncology</i> , <b>2013</b> , 7, 235-45	1.8	15
101	Unravelling the role of denosumab in prostate cancer. <i>Lancet, The</i> , <b>2011</b> , 377, 785-6	4.0	15
100	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 743-53	5.2	15
99	Targeted therapies in the treatment of urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 465-472	2.8	13
98	Angiogenesis inhibitors in prostate cancer therapy. <i>Discovery Medicine</i> , <b>2010</b> , 10, 521-30	2.5	13
97	Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?. <i>Cancer Therapy</i> , <b>2007</b> , 5A, 151-160		12
96	Role of immunotherapy in bladder cancer. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 26, 100296	2	11
95	Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 462-464	2.8	10
94	Mucosa-associated lymphoma tissue of the dura presenting as meningioma. <i>Southern Medical Journal</i> , <b>2010</b> , 103, 950-2	0.6	10
93	A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). <i>Annals of Oncology</i> , <b>2016</b> , 27, vi292	10.3	10
92	Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 657-666	4.6	9
91	Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e341-5	3.3	9
90	Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery. <i>Cancer Investigation</i> , <b>2012</b> , 30, 300-8	2.1	9
89	Radium-223 for the treatment of castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 1103-9	4.4	8
88	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , <b>2020</b> , 12, 819-831	3.8	7
87	A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1059-73	5.9	7
86	Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 144-7	2	7
85	The promising role of nivolumab in renal cell cancers. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 123-4	4.6	6

84	Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, e24-6	3.3	6
83	Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 651-64	2.9	6
82	Primary diffuse large B-cell lymphoma of the ureter in a patient with HIV: a case report and review of literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 324-6	2	6
81	Positron emission tomography findings in clinical mimics of lymphoma. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1228, 19-28	6.5	6
80	Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2010</b> , 7, 31-35		6
79	The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. <i>Asian Journal of Andrology</i> , <b>2021</b> , 23, 1-2	2.8	6
78	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. <i>Future Oncology</i> , <b>2016</b> , 12, 2049-58	3.6	5
77	Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 436-442	3.3	5
76	Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1299-300	4.6	5
75	Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 805-6	2.8	5
74	Active surveillance for prostate cancer: has the time finally come?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e265-6; author reply e267	2.2	5
73	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 330-336	7.1	5
72	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4169-70	2.2	4
71	Advances in systemic therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 2213-26	3.6	4
70	Reimbursement policy and androgen-deprivation therapy for prostate cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 579-80; author reply 580	59.2	4
69	Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?. <i>Oncologist</i> , <b>2008</b> , 13, 1314; author reply 1315	5.7	4
68	Maintenance avelumab for metastatic urothelial cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 1095-1096	4.6	4
67	Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 6-7	4.6	4

66	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 487-487	2.2	4
65	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 262-275	7.1	3
64	Epithelioid Angiosarcoma of the Bladder: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e1091-e1095	3.3	3
63	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 330-336	7.1	3
62	2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, S476	7.5	3
61	About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?. <i>Annals of Oncology</i> , <b>2010</b> , 21, 183-4	10.3	3
60	Further analysis of the survival benefit of clodronate. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2221-2	4.6	3
59	Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATP (bevacizumab, docetaxel, thalidomide, and prednisone). <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1959-1964	3.2	3
58	Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 425-425	2.2	3
57	Molecular profiling of aggressive variant urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 378-378	2.2	3
56	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2021</b> , 15, 11795549211044963	1.8	3
55	Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Cancer Management and Research</i> , <b>2017</b> , 9, 299-306	3.6	2
54	Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 914	2.2	2
53	Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2296-2297	2.2	2
52	Advances with androgen deprivation therapy for prostate cancer.. <i>Expert Opinion on Pharmacotherapy</i> , <b>2022</b> , 1-19	4	2
51	Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 402-402	2.2	2
50	Darolutamide for treatment of castration-resistant prostate cancer. <i>Drugs of Today</i> , <b>2020</b> , 56, 185-193	2.5	2
49	The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2016</b> , 16, 1166-71	2.2	2

48	The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2016</b> , 18, 592-3	2.8	2
47	Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2020</b> , 22, 76-78	2.8	2
46	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , <b>2020</b> , 47, 457-467	2.9	2
45	Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1889-1899	4	2
44	Pembrolizumab use in bladder cancer: a tale of two trials. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 577-578	5.5	2
43	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10s1, CMO.Ss30751	1.8	2
42	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	2
41	The Clinical Utility of Bevacizumab <b>2008</b> , 375-385		2
40	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2015</b> , 11, 2395-403	3.6	1
39	Hematuria in sickle cell trait: the importance of ruling out occult cancer. <i>Annals of Hematology</i> , <b>2012</b> , 91, 137-8	3	1
38	Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 803-4	2.8	1
37	The use of 5-alpha reductase inhibitors for the prevention of prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 11-2	4.6	1
36	Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2010</b> , 10, 593-600	2.2	1
35	Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e261; author reply e262	2.2	1
34	Cytotoxic compounds in the treatment of castration-resistant prostate cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2009</b> , 9, 1040-5	2.2	1
33	Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 179-179	2.2	1
32	A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5065-5065	2.2	1
31	Retrospective review of clear cell and non-clear cell renal carcinomas: Characteristics and course in the pre-TKI (tyrosine kinase inhibitor) and post-TKI era.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16052-e16052	2.2	1

30	Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 99-99	2.2	1
29	Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2019</b> , 21, 107-108	2.8	1
28	Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: A pathoepidemiological analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 403-403	2.2	1
27	Non-urothelial bladder cancer: Genomic alterations and patient outcomes.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 399-399	2.2	1
26	Implications for chemoprevention of prostate cancer with intake of cruciferous vegetables. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 357-8	2.8	1
25	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4520-4520 <sup>1</sup>	2.2	1
24	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. <i>Kidney Cancer</i> , <b>2019</b> , 3, 81-91	0.6	1
23	Plasmacytoid Variant of Urothelial Carcinoma: Poor Prognostic Variant with High Expression of CDH1 Mutation. <i>Uro</i> , <b>2021</b> , 1, 23-29		1
22	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. <i>Nature Communications</i> , <b>2022</b> , 13, 1878	17.4	1
21	Mucinous Signet-Ring Urachal Carcinoma of the Bladder: Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e889-e891	3.3	0
20	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 483-490	3.5	0
19	Characterization of Brain Metastases in Urothelial Cancers. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e679-e683	3.9	0
18	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. <i>Oncoscience</i> , <b>2021</b> , 8, 40-45	0.8	0
17	Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5079-5079	2.2	0
16	Contemporary treatment and survival differences in patients with urothelial versus nonurothelial bladder and upper tract carcinomas: Analyses from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 463-463	2.2	0
15	Circulating Tumor Cells <b>2014</b> , 19, 229-233		
14	New Pharmacotherapies in the Treatment of Advanced Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , <b>2010</b> , 4, CMU.S5075		0
13	. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7749	12.9	



- |    |  |     |
|----|--|-----|
| 12 | Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. <i>BJU International</i> , <b>2007</b> , 100, 1245-8  | 5.6 |
| 11 | Molecular characterization of brain metastases in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 509-509   | 2.2 |
| 10 | Characterization of differences between prostate cancer (PCa) patients presenting as de novo versus primary progressive metastatic disease.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 285-285   | 2.2 |
| 9  | Pilot study assessing distressors affecting patients with cancer using the distress screening tool.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 68-68   | 2.2 |
| 8  | Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 74-74   | 2.2 |
| 7  | Incidence and characterization of pure non-urothelial bladder and upper tract cancers: A 10-year review.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 414-414  | 2.2 |
| 6  | Survival outcomes for de novo versus primary progressive metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 258-258  | 2.2 |
| 5  | Survival outcomes and patterns of utilization of cytoreductive nephrectomy in the tyrosine kinase inhibitors (TKI)-era in metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC): Analyses from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16868-e16868 | 2.2 |
| 4  | Investigational Angiogenesis Inhibitors <b>2010</b> , 225-232  |     |
| 3  | Comparative analyses of survival differences in patients with urothelial versus non-urothelial upper tract carcinomas: Results from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16582-e16582  | 2.2 |
| 2  | Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHARTED. <i>Asian Journal of Andrology</i> , <b>2016</b> , 18, 444-5   | 2.8 |
| 1  | The emerging role of checkpoint inhibitors for rare genitourinary cancers. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 133-134   | 5.5 |